ArticleGenome medicine2012
Pharmacogene regulatory elements: from discovery to applications.
Article in Genome medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Deciphering single-cell gene expression variability and its role in drug response.Human molecular genetics · 2024Article
- CREdb: A comprehensive database of Cis-Regulatory Elements and their activity in human cells and tissues.Epigenetics & chromatin · 2024Article
- Identification of drug responsive enhancers by predicting chromatin accessibility change from perturbed gene expression profiles.NPJ systems biology and applications · 2024Article
- Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.Nature communications · 2024Article
- Essential Characteristics of Pharmacogenomics Study Publications.Clinical pharmacology and therapeutics · 2019Review
- ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression.Pharmacogenetics and genomics · 2017Article
- Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines.The pharmacogenomics journal · 2017Article
- In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus.Drug metabolism and disposition: the biological fate of chemicals · 2017Article
- Genomic Characterization of Metformin Hepatic Response.PLoS genetics · 2016Article
- Uncovering drug-responsive regulatory elements.Pharmacogenomics · 2015Review
- Characterization of regulatory sequences in alternative promoters of hypermethylated genes associated with tumor resistance to cisplatin.Molecular and clinical oncology · 2015Article
- Differential Gene Expression in Age-Related Macular Degeneration.Cold Spring Harbor perspectives in medicine · 2014Review
- Genome-wide discovery of drug-dependent human liver regulatory elements.PLoS genetics · 2014Article
- Disruption of long-range gene regulation in human genetic disease: a kaleidoscope of general principles, diverse mechanisms and unique phenotypic consequences.Human genetics · 2014Review
- ABCC4 is regulated by microRNA-124a and microRNA-506.Biochemical pharmacology · 2014Article
- Integrating multiple oestrogen receptor alpha ChIP studies: overlap with disease susceptibility regions, DNase I hypersensitivity peaks and gene expression.BMC medical genomics · 2013Article
- Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulatory elements play an important role in the variability of individual responses to drug treatment. This has been established through studies on three classes of elements that regulate RNA and protein abundance: promoters, enhancers and microRNAs. Each of these elements, and genetic variants within them, are being characterized at an exponential pace by next-generation sequencing (NGS) technologies. In this review, we outline examples of how each class of element affects drug response via regulation of drug targets, transporters and enzymes. We also discuss the impact of NGS technologies such as chromatin immunoprecipitation sequencing (ChIP-Seq) and RNA sequencing (RNA-Seq), and the ramifications of new techniques such as high-throughput chromosome capture (Hi-C), chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) and massively parallel reporter assays (MPRA). NGS approaches are generating data faster than they can be analyzed, and new methods will be required to prioritize laboratory results before they are ready for the clinic. However, there is no doubt that these approaches will bring about a systems-level understanding of the interplay between genetic variants and drug response. An understanding of the importance of regulatory variants in pharmacogenomics will facilitate the identification of responders versus non-responders, the prevention of adverse effects and the optimization of therapies for individual patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.